High threshold clinical responses (Investigator’s Global Assessment Score 0 or 1, and Psoriasis Area and Severity Index ... while IZAR-2 will enroll patients with an inadequate response to tumor ...

The use of IL-17 inhibitors in patients with psoriasis was associated with an increased risk for fungal infections when compared with other biologics.

Tumour Necrosis Factor TNF is crucial for defence but can drive chronic inflammation linked to arthritis and autoimmune diseases when overproduced ...

While biologic therapies have revolutionized psoriasis treatment, GI adverse effects such as ... odds ratio (ROR), 0.76), followed by IL-23 inhibitors (ROR, 0.44) and anti-TNF-α agents (ROR, 0.41).

Investigators aimed to highlight aspects that may predict the time to relapse among patients with psoriasis who discontinued use of biologic therapy.